Article

Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in <i>NRAS</i> -Mutated Melanoma

2025-12-21

Abstract excerpt

<h4>ABSTRACT</h4> Most patients with advanced BRAF or NRAS -driven melanoma receive front-line immunotherapy. However, if immunotherapy fails, BRAF -mutated patients have effective second-line therapies, whereas NRAS -mutated patients lack pathway-targeted options. Recently, RAS(ON) multi-selective inhibitors like RMC-7977, and the investigational agent daraxonrasib, were described that, in partnership with c...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: cd656512-f18c-5452-9a51-1df116a2817f
DOI: 10.64898/2025.12.18.695203

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in <i>NRAS</i> -Mutated MelanomaDOI 10.64898/2025.12.18.695203Read

Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma.Semantic proximity Read

A mutation-resolved therapeutic atlas of NRAS-mutant melanoma reveals genotype-selective response to RAS(ON) inhibition and adaptive STAT3 survivalSemantic proximity Read

NRAS mutant melanoma: Towards better therapies.Semantic proximity Read

BRAF inhibitors: resistance and the promise of combination treatments for melanomaSemantic proximity Read

Targeting the MAPK pathway for NRAS mutant melanoma: from mechanism to clinic.Semantic proximity Read

Modelling targeted therapy efficacy in NRAS mutant conjunctival melanoma.Semantic proximity Read

Beyond BRAF: where next for melanoma therapy?Semantic proximity Read

Targeting RAS/RAF/MEK/ERK signaling in metastatic melanomaSemantic proximity Read

Targeting mutant NRAS signaling pathways in melanoma.Semantic proximity Read

Detecting mechanisms of acquired BRAF inhibitor resistance in melanoma.Semantic proximity Read

<em>NRAS</em>-mutant melanoma: current challenges and future prospectSemantic proximity Read

The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?Semantic proximity Read